

## **NUS Medicine and Cyclotek to strengthen radiopharma capability in Singapore and across ASEAN region**

08 December 2025 | News

### **To support talent development and specialised training in radiopharmaceutical science**



Singapore-based NUS Medicine's Clinical Imaging Research Centre (CIRC), a leading academic centre for advanced molecular imaging, and Cyclotek, one of Australia and New Zealand's premier radiopharmaceutical manufacturers and distributors, have announced a strategic collaboration to enhance radiopharmaceutical development, clinical trials, and precision diagnostic capability across Singapore and the wider ASEAN region.

The partnership brings together CIRC's imaging and clinical trial research experience with Cyclotek's established manufacturing network, GMP and CDMO capabilities. Together, the organisations aim to create a stronger, more connected, and innovation-ready radiopharmaceutical ecosystem that can deliver earlier diagnosis, more accurate disease characterisation, and improved access to next-generation diagnostic and therapeutic agents.

The collaboration will explore opportunities to:

- Increase access to Investigational Medicinal Products (IMPs) for clinical trials in Singapore and ASEAN
- Strengthen regional supply resilience for emerging diagnostic and radioligand therapy products
- Evaluate and translate promising radiopharmaceuticals from research settings into clinical practice
- Expand opportunities for cross-border clinical trials and translational research

As the collaboration develops, both organisations will also explore future opportunities to support talent development and specialised training in radiopharmaceutical science and advanced molecular imaging, strengthening the long-term workforce capabilities essential for a sustainable regional ecosystem.

The partnership is expected to increase access to PET radiopharmaceuticals for clinical research, support evaluation of emerging diagnostic and therapeutic agents, and improve supply reliability for investigational products. This will aid the earlier detection and characterisation of cancer, neurological diseases, and other serious conditions, contributing to better patient outcomes and improved health system resilience across ASEAN.

Image caption- *(Left) Jon Evans, CEO of Cyclotek International and (right) Prof Pek-Lan Khong, Director of the Clinical Imaging Research Centre (CIRC)*